Know Cancer

or
forgot password

Phase I Drug Interaction Clinical Study of Polyphenon E


Phase 1
18 Years
N/A
Not Enrolling
Both
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

Phase I Drug Interaction Clinical Study of Polyphenon E


OBJECTIVES:

Primary

- Determine the effect of green tea extract (Polyphenon E) on cytochrome P450 enzyme
activities and glutathione S-transferase activities and levels in healthy participants.

Secondary

- Determine the safety and tolerability of this drug in these participants.

OUTLINE: This is an open-label study.

Participants receive oral green tea extract (Polyphenon E) once daily for 4 weeks in the
absence of unacceptable toxicity.

Participants are followed for 2 weeks.

PROJECTED ACCRUAL: A total of 44 participants will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Healthy individuals

- Non-smokers

- More than 1 year since smoking cessation

- No concurrent smokers

- No regular consumption of large amounts of alcohol

- On average, ≤ 3 alcoholic drinks per week

- Consumes < 6 cups or glasses of tea per week

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance Status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Bilirubin ≤ 2.0 mg/dL

- AST or ALT ≤ 2 times normal

- Alkaline phosphatase ≤ 2 times normal

Renal

- Creatinine ≤ 1.5 mg/dL

Cardiovascular

- Resting systolic blood pressure ≥ 100 mm Hg

- No hypertension or hypercholesterolemia requiring unscheduled medical visits or
changes in treatment within the past 3 months

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Willing to refrain from tea and related products and oral herbal/botanical
supplements during study participation

- Willing to limit the consumption of cruciferous vegetables to ≤ once a week during
study participation

- Willing to refrain from caffeine-containing food or beverages (e.g., coffee, colas,
chocolate, or over-the-counter medications) for 72 hours before, during, and for 8
hours after study drug administration

- Willing to refrain from food items that affect drug or carcinogen metabolizing
enzymes (e.g., grapefruit, grapefruit juice, cruciferous vegetables, and food cooked
over charcoal) for 72 hours before, during, and for 8 hours after study drug
administration

- No difficulty swallowing capsules or tablets

- No metabolic disorder known to affect study drugs

- No other serious acute or chronic disease (e.g., type I or II diabetes, cystic
fibrosis, or active infection)

- No known hypersensitivity to green tea or probe drugs (e.g., caffeine,
dextromethorphan, losartan, or buspirone)

- No invasive cancer (i.e., non-skin cancer) within the past 5 years

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Other

- More than 3 months since prior participation in another clinical intervention study

- No concurrent medications or supplements that are known P450 enzyme inducers or
inhibitors

Type of Study:

Interventional

Study Design:

Masking: Open Label, Primary Purpose: Prevention

Principal Investigator

H. H. Sherry Chow, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Arizona

Authority:

United States: Federal Government

Study ID:

CDR0000387801

NCT ID:

NCT00091325

Start Date:

October 2004

Completion Date:

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific

Name

Location

Arizona Cancer Center at University of Arizona Health Sciences CenterTucson, Arizona  85724